Independent group finds new cholesterol drugs far too costly

(Reuters) - An independent non-profit organization that evaluates clinical and cost effectiveness of new medicines said announced prices for a just-approved class of potent cholesterol lowering drugs were far too high, according to a draft report released on Tuesday.

Latest health news from http://reuters.us.feedsportal.com/c/35217/f/654207/s/49adc6bc/sc/28/l/0L0Sreuters0N0Carticle0C20A150C0A90C0A80Cus0Edrugs0Echolesterol0Eprices0EidUSKCN0AR82QY20A150A90A80DfeedType0FRSS0GfeedName0FhealthNews/story01.htm